Drugs / RC148
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06883630 | Mar 2025 → Aug 2026 overdue | non-small cell lung carcinoma | RemeGen Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06016062 | Sep 2023 → Dec 2025 overdue | cancer | RemeGen Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06038396 | Aug 2023 → Feb 2026 overdue | neoplasm | RemeGen Co., Ltd. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06642545 | Feb 2025 → Oct 2026 expected | breast cancer | RemeGen Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07462143 | May 2026 → May 2027 expected | colorectal cancer | RemeGen Co., Ltd. | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07416474 | Apr 2026 → Dec 2027 expected | non-small cell lung carcinoma | RemeGen Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RC148 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06883630 ↗ |
| Route | Intravenous | “RC148 injection will be administered as an intravenous (IV) infusion” NCT06016062 ↗ |